What Cloflam Treats: Main Uses and Benefits

Cloflam (Clobetasol Propionate) is generally reserved for providing very potent, strong symptomatic relief in severe and resistant skin conditions. Its therapeutic role may assist with reducing the most distressing manifestations of disease activity when lower-potency treatments have proven insufficient. It is primarily used for the management of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, including active, localized cases of severe plaque psoriasis and refractory eczema.

---

Key Therapeutic Focus

This medication is commonly used across conditions characterized by periods of heightened symptoms that have become challenging to manage. It helps address symptom clusters that may become intense or disruptive, particularly symptoms related to inflammatory or irritative states, such as itching (pruritus), redness, swelling, and skin thickening. Its use contributes to improved comfort during periods of heightened symptoms, offering symptomatic relief that may help patients cope more steadily with difficult episodes. It supports the stabilization of lesions, especially in high-resistance areas like the palms, soles, or scalp.

“Applied in scenarios where additional management of discomfort is required for chronic dermatoses.”

---

Quick Fact: Relief for Intense Pruritus

Regulatory References

1. NIH DailyMed Drug Labeling

Cloflam (Clobetasol Propionate) is a super-high potency medicine governed by strict population eligibility rules in official regulatory documents.

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adults (18 years and older): Generally the target population.
• Adolescents (12-17 years): Allowed for corticosteroid-responsive dermatoses with some formulations (e.g., ge12 years).

Populations for whom use is not recommended (if applicable):

• Pediatric patients under 12 years of age: Use is not recommended; safety and effectiveness have not been established.
• Patients under 18 years of age: Use is not recommended for certain high-potency formulations due to potential HPA axis suppression risk.

Populations for whom use is contraindicated:

• Patients with a history of hypersensitivity to the drug or any component.
• Patients with rosacea, perioral dermatitis, or acne vulgaris.
• Patients with untreated cutaneous infections (viral, fungal, bacterial).
• Dermatoses in children under one year of age.

Age-Related Eligibility Rules

Age Group	Regulatory Status
Infants (Under 1 Year)	Contraindicated for all dermatoses.
Children (Under 12 Years)	Not recommended; safety is not established.

Condition-Specific Eligibility Rules

• Application Site: The medicine must not be used on the face, groin, or axillae due to the risk of atrophic changes.
• Liver Impairment: Recognized as a risk factor that predisposes a patient to HPA axis suppression due to increased systemic absorption.
• Pregnancy Status (Category C): Should be used only if the potential benefit justifies the potential risk to the fetus.
• Lactation: Caution should be exercised when administered to a nursing woman.

Connection to the overall eligibility profile: Regulatory documents define strict limits for Cloflam, with absolute contraindications based on specific conditions and application sites. Eligibility is further structured by age-based exclusions, with use generally not established for children under 12, and a conditional status assigned during pregnancy and lactation due to systemic absorption risk.

Cloflam, a combination medicine containing diclofenac (an NSAID) and serratiopeptidase, may interact with several other medicines. These interactions can potentially increase the risk of side effects or alter the effectiveness of the drugs involved. Always inform your healthcare provider of all prescription, over-the-counter, and herbal supplements you are currently taking.

Increased Risk of Bleeding or Gastrointestinal Issues

The most significant concern involves medicines that affect blood clotting or the gastrointestinal (GI) tract. The risk of stomach ulcers, bleeding, or perforation may be substantially increased when Cloflam is taken with:

Interacting Medicine Category	Examples	Potential Outcome
Blood Thinners (Anticoagulants/Antiplatelets)	Warfarin, Aspirin, Clopidogrel	Increased risk of serious bleeding.
Other Non-Steroidal Anti-inflammatory Drugs (NSAIDs)	Ibuprofen, Naproxen	Increased risk of GI side effects.
Corticosteroids	Prednisolone	Higher risk of stomach ulcers and GI bleeding.
Certain Antidepressants	SSRIs, SNRIs	Increased risk of GI bleeding.

Effects on Other Medications

Cloflam may also interfere with the efficacy of certain drugs or increase the concentration of others in the blood:

• Blood Pressure Medications (Antihypertensives): Diclofenac can reduce the effectiveness of diuretics, ACE inhibitors, and beta-blockers, potentially worsening blood pressure control and increasing the risk of kidney problems.
• Lithium and Methotrexate: Cloflam may cause an elevation in the blood levels of lithium and methotrexate, which can increase the risk of toxicity and related side effects. Close monitoring is essential if these drugs are co-administered.
• Cyclosporine: Co-administration may increase the risk of kidney damage.

Other Interactions

Avoid consuming alcohol while taking Cloflam, as this combination significantly raises the risk of severe gastrointestinal bleeding and ulcers. Serratiopeptidase is not known to have major interactions with most medications, but the diclofenac component requires careful consideration of all potential interactions.

Modulating the Cyclooxygenase Enzyme System

Cloflam acts as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes, targeting both the COX-1 and COX-2 isoforms. This interaction blocks the active site of these key biological targets, preventing the conversion of arachidonic acid into various prostaglandins—a critical step in the arachidonic acid cascade. This suppression of enzyme activity initiates a mechanistic cascade that modulates physiological signaling at the cellular level.

Systemic Physiological Consequence

The resulting reduction in prostaglandin production alters multiple downstream signaling events. Specifically, the mechanism reduces the concentration of these mediators, which are involved in increasing vascular permeability and contributing to afferent nerve signaling. This leads to a reduction in nerve receptor sensitization and a subsequent modulation of nociception. This action produces a change in the steady-state activity of the targeted peripheral and central physiological systems.

How to Use Cloflam: Official Administration Guidelines

Cloflam (Clobetasol Propionate) is a super-high potency medication whose use is characterized by established parameters that define a specific, short-course administration pattern.

---

Administration Scope

Instruction Category	Official Guideline
Route of administration	Administration is topical/cutaneous to the affected skin area only. An ophthalmic route exists for a separate eye-specific suspension form.
Dosing schedule	Apply a thin layer to the affected area(s). The total amount used must not exceed 50 grams (or 50 mL) across all applications per week.
Frequency and timing	The standard schedule is twice daily (morning and evening) for most forms, or once daily for the shampoo form. The duration of therapy is typically limited to 2 consecutive weeks.
Preparation requirements	The shampoo form must be applied to the dry scalp and allowed to remain for 15 minutes before rinsing. Flammable forms must be kept away from heat and flame during use.
Age-group administration	Use is generally not recommended in pediatric patients under 12 years of age for most topical forms, establishing an age-related boundary on application.
Procedural conditions	The treated area must not be covered with an occlusive dressing (bandage or wrap) unless specifically directed. Application must be avoided on the face, axillae (armpits), and groin.

---

Connection to the Overall Use Protocol

The clinical use protocol is defined by parameters regarding quantity, site avoidance, and duration. These standards ensure that the high-potency product is administered as a short-term, time-bound regimen, and is discontinued once control of the condition has been achieved, thereby structuring the medication's proper clinical administration.

Research evidence / Overview of Studies for Cloflam

The evidence landscape for Cloflam, which contains the ingredient Clobetasol Propionate, is primarily based on clinical trials conducted to evaluate the effects of the study drug for specific, severe skin conditions. Research has explored the patterns of change in symptoms during short, defined study periods. The findings described here reflect what has been observed so far in regulated studies and contribute to the broader evidence landscape, but research does not determine whether an individual will respond similarly.

Evidence for use in Severe Plaque Psoriasis

Research exploring short-term symptom changes in severe plaque psoriasis has primarily relied on Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time by comparing the Cloflam formulation against an inactive base (a vehicle) or sometimes against other active treatments. The main populations included were adults with moderate-to-severe plaque psoriasis, including studies specific to the scalp. Studies monitored outcomes describing episodic or acute changes, such as the overall assessment of the plaques by investigators and standardized tools like the PASI score.

Short-term trials reported measurements showing differences in the average change in severity scores between the active treatment group and the vehicle control group over a period of 2 to 4 weeks. Research described patterns regarding the time required for measured changes in visible signs, such as plaque thickness and redness, to evolve in the observed populations.

Evidence for use in Refractory Eczema

For conditions like chronic or refractory eczema, research was evaluated in Randomized Comparative Trials where the study drug was evaluated in comparison to a vehicle or an alternative treatment. The study populations were mainly adults whose condition had been documented as unresponsive to lower-potency treatments. Outcomes linked to inflammatory or irritative states were monitored, including overall disease activity and patient-reported outcomes describing perceived discomfort, such as the severity of itching.

What is Still Uncertain About the Research for Cloflam

Research highlights what is known—and what is still uncertain—about this medication. One of the primary research limitation frames is that evidence is limited, as the core studies focused exclusively on short treatment intervals. Follow-up durations were limited, meaning that the research does not fully define the long-term pattern of symptom changes over many months or years. Subgroup findings are uncertain for many special populations, including younger children, reinforcing that research provides context but not individual predictions outside of the studied groups.

Key Studies & References

1. Label: CLOBETASOL PROPIONATE cream (FDA/DailyMed Product Monograph)
2. Public Assessment Report Scientific discussion Eczoria 0.5 mg/g cream (clobetasol propionate) (EMA/NL)
3. Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial
4. Corticosteroids for treating oral lichen planus (Cochrane Review, addressing pain and lesion size outcomes)

Common questions about Cloflam (FAQ)

Q: Is Cloflam considered an NSAID or another class of drug?

Official product information indicates that 'Cloflam' may refer to different drug classes depending on the specific formulation. Some versions contain diclofenac, classifying them as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Other formulations are classified as a super-high potency topical corticosteroid, such as Clobetasol Propionate.

Q: What are the most common gastrointestinal side effects of Cloflam reported in studies?

According to the official label for the NSAID component, common gastrointestinal (GI) side effects can include nausea, heartburn, abdominal pain, and indigestion. It is important to know that regulatory warnings also identify serious GI risks, such as internal bleeding, inflammation, and ulceration.

Q: What does official guidance say about using Cloflam if a person has high blood pressure?

Regulatory guidance for the NSAID component indicates that these medicines can potentially cause new or worsening high blood pressure (hypertension). People with existing fluid retention or hypertension are therefore advised to use the medication with caution. Monitoring of blood pressure may be recommended or relevant during treatment.

Q: Are the side effects of Cloflam potentially worse for older adults?

Official information notes that older adults may experience an increased risk of side effects. This is because age-related changes can affect how organs like the liver and kidneys process and remove the drug from the body. Due to this potential for higher drug levels, changes to the regimen may require consultation with a healthcare provider.

Q: What is the main purpose of the medicine Cloflam?

The approved use for Cloflam varies by formulation. The topical steroid form is primarily indicated for the short-term treatment of inflammatory skin conditions like moderate to severe plaque psoriasis. The oral NSAID combination is typically used for the management of pain and inflammation, such as those related to soft tissue injuries.

Q: Can Cloflam cause drowsiness or affect a person's ability to drive?

Official product information for the oral formulation notes that dizziness, drowsiness, or visual disturbances may occur. Official labels advise caution regarding driving or operating heavy machinery if these effects are experienced. Systemic absorption of the topical form has also been associated with general fatigue or lethargy.

Q: Can women who are breastfeeding take Cloflam according to regulatory documents?

Due to the possibility of the drug components passing into breast milk, regulatory documents advise caution when considering use while breastfeeding. Official guidance suggests that if the topical steroid is used near the breast, the area should be thoroughly cleaned before nursing.

Q: What warnings are issued regarding Cloflam use and pre-existing heart conditions?

The NSAID component carries a prominent regulatory warning about an increased risk of serious cardiovascular thrombotic events, such as heart attack and stroke. This potential risk can begin early in treatment. Furthermore, the drug is formally advised against for the treatment of pain immediately following coronary artery bypass graft (CABG) surgery.

Q: What are the signs of a serious allergic reaction to Cloflam?

Official labels describe the potential for serious allergic reactions, including anaphylaxis. Signs can include difficulty breathing, swelling of the face, tongue, or throat, and severe hives. Additionally, severe skin reactions like Stevens-Johnson Syndrome (SJS) have been reported with the NSAID class of drugs.

Q: What are the general risks associated with an accidental overdose of Cloflam?

For the topical steroid formulation, general risks associated with overuse or accidental ingestion involve systemic absorption. This can potentially lead to the suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis, which may result in serious conditions like adrenal insufficiency or Cushing's syndrome.

Q: Is it true that Cloflam is primarily broken down (metabolized) by the liver?

Official pharmacokinetic information confirms that both the NSAID component and the topical steroid component are primarily processed (metabolized) by the liver. Regulatory documents note that existing severe liver impairment is associated with an increased risk of adverse effects.

Q: Can people with asthma or a history of respiratory issues use Cloflam?

The NSAID component is formally advised against (contraindicated) for individuals who have a history of asthma, hives, or allergic reactions after taking aspirin or other NSAIDs. This is due to the potential risk of inducing severe, sometimes fatal, bronchospasm (sudden airway narrowing).

Q: Why do official sources suggest taking Cloflam with food? (Seeking justification)

Official directions for the oral NSAID combination often suggest taking the medication with or right after food. This measure is intended to help decrease the likelihood of gastrointestinal side effects, such as stomach upset, indigestion, or the more serious risks of ulcers and bleeding.

Q: What is the reason for any prominent regulatory warnings (like a 'black box') associated with Cloflam?

The NSAID component carries a prominent Boxed Warning in regulatory documents. This serious warning is primarily related to the risk of life-threatening cardiovascular events, such as heart attack and stroke, and the potential for serious gastrointestinal (GI) bleeding, ulcers, and perforation.

Q: Are there any specific groups of people who are formally advised to avoid Cloflam entirely?

Regulatory information identifies several groups formally advised to avoid the oral formulation. These contraindications include individuals with severe or recurrent stomach ulcers, those with severe heart failure, people allergic to aspirin/NSAIDs (due to asthma risk), and patients recently undergoing coronary artery bypass graft (CABG) surgery.

Q: Can Cloflam cause changes in mood, such as increased anxiety or depression?

Changes in mood, including reports of increased anxiety or depression, are noted as possible adverse reactions in regulatory documents. For the topical steroid form, these may be linked to the systemic effect of Cushing's syndrome. The oral NSAID label also lists these as central nervous system side effects.

Q: Does long-term use of Cloflam affect bone density or bone health?

Prolonged use of the high-potency topical steroid formulation can potentially lead to systemic absorption, which carries the risk of HPA axis suppression. As a class effect of corticosteroids, systemic exposure can affect bone health and has been associated with decreased bone mineral density or osteoporosis.

Q: What official research supports the use of Cloflam for its main approved indication?

The official indications for Cloflam are supported by the findings of controlled clinical trials, most notably Randomized Controlled Trials (RCTs). These studies compare the medication to a non-active base or an alternative drug. Researchers observed changes over short treatment periods using standardized measures, such as the PASI score for skin conditions.

How to Store and Dispose of Cloflam?

The storage and disposal of Cloflam (Clobetasol Propionate) must adhere to official regulatory requirements to maintain product stability and ensure safety.

---

️ Storage Requirements

• Temperature: Store at Controlled Room Temperature, typically 20 C to 25 C. Brief temperature excursions between 15 C and 30 C are permitted.
• Prohibitions: Do not refrigerate and do not freeze the product.
• Protection: Keep the container tightly closed in its original packaging.
• Child Safety: Like all medicines, keep Cloflam out of the sight and reach of children.

---

️ Disposal Instructions

Unused or expired product must be disposed of according to local requirements. It is officially required that the medicine not be thrown into wastewater (e.g., flushed down the toilet) to prevent environmental contamination.